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The aminocyclopropyl unit is present in a wide range of biologically active natural products
and pharmaceuticals.1 Traditional approaches to the synthesis of aminocyclopropanes include
the Curtius rearrangement of cyclopropylcarboxylic acids,2 the reduction of
nitrocyclopropanes,3 the reductive amination of cyclopropanone acetals4 and the
cyclopropanation of enamines.5 More recently, de Meijere has demonstrated a new titanium
mediated cyclopropanation of amides or nitriles using 1,2-dimetallic derivatives of
monosubstituted alkenes.6 By way of contrast however, the search for simple and
experimentally convenient methods for the direct addition of heteroatom substituted
carbenoids to unactivated alkenes has proven to be more elusive, with direct
alkoxycyclopropanation and aminocyclopropanation requiring the use of such reagents as
stoichiometric Fischer carbene complexes.7 As an extension of our earlier studies on the
cyclopropanation of alkenes using organozinc carbenoids prepared from simple carbonyl
compounds8 or their derived acetals,9 we have previously demonstrated that orthoformates are
useful precursors for direct alkoxycyclopropanation.10 More recently, we have also shown
that diethoxymethylpyrrolidinone can be used for generation of an amido substituted
organozinc carbenoid,11 and that selection of a chiral oxazolidinone congener leads to an
asymmetric version of this amidocyclopropanation reaction.12 In the present paper, we wish to
report, in full, our detailed observations on the scope and limitations of simple achiral
diethoxymethylamide carbenoid precursors for the construction of densely functionalised
amidocyclopropanes.
From a mechanistic standpoint, we envisaged that the evolution of a suitably functionalised
amidoorganozinc carbenoid from a diethoxymethylamide 1 could proceed as shown in
Scheme 1. Thus, coordination of a Lewis acid (either ZnCl2 or Me3SiCl) to one of the ethoxy
groups of the amide 1 leads to the formation of cation 2 which can be reduced by two electron
delivery from metallic zinc to give the organozinc derivative 3. Lewis acid mediated SN1
displacement of the remaining ethoxy group by chloride then formally leads to the organozinc
carbenoid which could exist as either the tetrahedral form 4 or the planar iminium form 5.
Scheme 1
The diethoxymethylamide carbenoid precursors 12-17 were initially prepared by heating the
corresponding amides 6-11 in a large excess of triethyl orthoformate in the presence of a
catalytic amount of aluminium chloride according to a literature procedure (Scheme 2 and
Table 1).13 However, this method is inconvenient, particularly on larger scales, due to the
difficulty in removing the large excess of orthoformate, and hence alternative methods were
investigated. We found that the diethoxymethyl derivative of pyrrolidinone 6 (Entry 1) could
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be conveniently prepared on a 10 g scale using only 2.6 equivalents of triethyl orthoformate in
the presence of chlorotrimethylsilane and a catalytic amount of triphenylphosphine at room
temperature. After purification by distillation, the dialkoxymethyllactam 12 was obtained in
61% yield. In a similar fashion, diethoxymethyloxazolidinone 13 (Entry 2) was obtained in
60% yield (10 g scale) using 2.6 equivalents of orthoester and a catalytic quantity of acetyl
chloride. This latter procedure is the most convenient but was not generally applicable to the
preparation of the other diethoxymethyl derivatives. It is notable that in this case the starting
oxazolidinone is insoluble in the reaction mixture and gradually dissolves as the reaction
progresses, and this gradual dissolution may well be important for the success of the reaction.
The yields are essentially comparable to the AlCl3 catalysed reactions and these methods
avoid the requirement for a large excess of triethyl orthoformate and the associated
purification problems which then arise.
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Scheme 2
a. (EtO)3CH, AlCl3, 155 °C (Method A). b. (EtO)3CH, cat. Me3SiCl, cat. PPh3, CH2Cl2, rt (Method B). c.
(EtO)3CH, cat. AcCl, rt (Method C).
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Table 1 a. Method A, b. Method B, c. Method C.
With the required diethoxymethylamides in hand, the amidocyclopropanation of a wide range
of alkenes was investigated using zinc, chlorotrimethylsilane and zinc chloride (Scheme 3 and
Table 2). In the initial reactions, zinc amalgam was employed as the metal source. Although
easily handled, the amalgam is undesirable due to the toxicity and environmental issues
associated with the use of mercury and its salts. Moreover, we have also observed that the
zinc amalgam has a tendency to form hard spheres during the course of the cyclopropanation
reactions which can lead to variable yields, presumably due to the large decrease in the
available surface area of the metal. To this end, we were keen to investigate alternative metal
sources, and the use of zinc dust, together with a catalytic quantity of copper (I) chloride, was
found to be a perfectly acceptable substitute, giving the amidocyclopropanes in comparable
yields (Entry 1). The formation of hard metal spheres during the course of the reactions is also
no longer observed.
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Table 2 a. Zn(Hg) method. b. Zn/CuCl method. c. The carbenoid precursor was added by syringe pump over 2 h.
d. Reaction carried out at room temperature. e. Selectivities in parentheses refer to purified material.
The cyclopropane products 39-65 were obtained in moderate to good yields with a wide
variety of alkenes. All of the carbenoid precursors could be employed in the
amidocyclopropanation reaction with the exception of diethoxymethylphthalimide 14. Since
the phthalimide functional group is known to be reduced under dissolving metal conditions,14
this observation is perhaps unsurprising. As anticipated, the amidocyclopropanation of
electron-rich alkenes (Entries 8 and 10) proceeded in higher yield than the
amidocyclopropanation of electron deficient alkenes (Entry 9) and in the cyclopropanation of
diene 38 (Entry 23), chemoselective cyclopropanation of the more electron-rich alkene was
observed. In terms of the steric environment, mono (Entries 1-3, 8, 10-13, 16, 18, 19, and 24-
26), di (Entries 4-6, 9, 14, 15, 20, 21, and 27), tri (Entries 7, 22, and 23) and tetrasubstituted
(Entry 17) alkenes were all readily cyclpropanated under the reaction conditions and a variety
of functional groups including esters, ethers, halides and silyl groups were tolerated. In the
case of highly volatile alkenes (Entry 17), it was more effective to carry out the
cyclopropanation reaction at room temperature. The stereochemistry of the major products
was assigned on the basis of 1H NMR coupling constants and simple proton decoupling
experiments where required. In most cases, a preference for the formation of the less-hindered
trans-amidocyclopropane was observed. However, the overall trends in selectivity from
substrate to substrate are difficult to rationalise. In general, mono-substituted alkenes tend to
favour the formation of the trans isomer with varying degrees of selectivity with larger
substituents leading to a higher preference for trans-cyclopropanation. Interestingly, the
presence of an allylic ether group reversed this selectivity (Entry 16), but an allylic or vinylic
ester did not (Entries 8, 10 and 13). This may indicate that coordination of the ether oxygen to
the zinc carbenoid during cyclopropanation can influence the stereochemical outcome and we
might expect this to be more favourable for an ether than an ester. The trends for more
substituted alkenes are much more difficult to rationalise. Cyclohexene 23 showed a strong
preference for the formation of the exo-cyclopropane (Entry 6), whereas for indene 31 the
reverse was true (Entries 14 and 27). Apparently similar systems such as methylcyclohexene
24 and carene 37 showed contrasting selectivities in the cyclopropanation reaction (Entries 7
and 22). A speculative explanation using a quadrant model (Figure 1) in which one quadrant
(A) is largely unhindered, but the adjacent quadrant (B) is sterically congested might help to
explain these results. Thus a monosubstituted alkene (R2=H) fits into the ‘pocket’ with the R1
substituent occupying the unhindered quadrant A in transition state (i). When a second
substituent is present on the alkene (R2≠H), the larger steric hindrance in quadrant B can lead
to the cis transition state (ii) becoming the favoured pathway, in which the two alkyl groups
occupy quadrants C and D where there is only moderate steric hindrance.
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Figure 1
A possible transition state in line with such a model is shown in Figure 2, in which the zinc
atom is located in quadrant D, and the orientation of the pyrrolidine ring is controlled by
coordination of the lactam oxygen to the metal centre. This places the lactam carbonyl in
quadrant C and the methylene adjacent to the nitrogen in quadrant B, leaving quadrant A
largely empty. Thus, a monosubstituted alkene (R2=H) can approach the carbenoid relatively
easily with the R1 group located in quadrant A, leading to a preference for trans-cyclopropane
formation (i). With more substituted alkenes (R2≠H), the unfavourable interaction between the 
lactam hydrogen atoms and R2 in the exo transition state (i) leads to a preference for the endo
transition state (ii) in which R1 is close to the zinc atom and R2 is close to the lactam carbonyl
group.
Figure 2
The use of a large excess of chlorotrimethylsilane in the reaction precluded direct
amidocyclopropanation of allylic alcohols, but a preliminary experiment (Scheme 4) with
allyl benzene 18 demonstrated that the cyclopropane 39 could be produced in the absence of
the silicon electrophile by employing a larger excess of zinc chloride (30% conversion).
When these alternative conditions were applied to the cyclopropanation of allyl alcohol, the
amidocyclopropyl alcohol 67 was obtained in low yield (8%, diastereomeric ratio trans:cis
2:1). However, when 2-cyclohexen-1-ol 68 was cyclopropanated under the same conditions,
the only isolated product was the ethyl ether 69, again in 8% yield. Cyclopropane ether 69 is
probably formed by initial displacement of the hydroxy group with ethanol under the Lewis
acidic conditions and then subsequent cyclopropanation of the allylic ether 70. Alkene 70 was
synthesised by alkylation of the alcohol 68, and cyclopropanated under the same conditions to
give the same cyclopropane 69 in 20% yield (diastereomeric ratio >8:1). Interestingly, the
ethyl ether appears to direct the approach of the organozinc carbenoid to the same face of the
ring.15 The exo-cyclopropane is also formed selectively in a similar fashion to the
cyclopropanation of cyclohexene above (Table 2, Entry 6).
R1
HH
R2
AB
C D
Zn
N
O
Cl
H
HH H
R1R2
H
C D
Zn
N
O
Cl
H
HH
(ii)(i)
AB
HO
OR
Ph
a
a
a
N
H
H
O
Ph
N
H
H
O
HO
HH
H
N
O
EtO
H
18 39
66 67
68 R = H
70 R = Et
69b
Scheme 4 a. 12, ZnCl2, Zn, CuCl, Et2O, 8% (67), 8% (69 from 68), 20% (69 from 70). b. NaH, DMF, EtI, 33%
based on recovered 68.
The cyclopropanes formed in these reactions are suitable for further elaboration into
derivatives of potential utility for incorporation as rigid conformational locks in a wide
variety of systems, such as chiral ligands or drug molecules (Scheme 5). The oxazolidinone
ring in cyclopropane 57 was opened under basic conditions to yield the aminoalcohol 71,
which was BOC protected and oxidised to the corresponding N-cyclopropylglycine derivative
73. Similarly, the benzoxazolidine ring in 65 can be opened using Super Hydride16 to give the
indenocyclopropylcatecholamine 74 in moderate yield. The cyclopropyl silane 50 was
oxidised under Tamao-Fleming conditions to give the corresponding amidocyclopropanol 75
in 35% yield. These examples provide a brief illustration of the interesting cyclopropylamino
acid and aminoalcohol units that can readily be prepared using amidoorganozinc carbenoids.
Densely functionalised cyclopropylamino acid 73 was obtained in only four steps from the
cheap commercially available alkene 20.
Scheme 5
a. LiOH, EtOH, H2O, 49%. b. BOC2O, Et3N, CH2Cl2, 72%. c. KMnO4, NaOH, tBuOH, H2O, 84%. d. LiEt3BH,
THF, 34%. e. TBAF, THF, rt then 30% H2O2, KHCO3, MeOH, 35%.
Finally, from a practical viewpoint, it would be much more convenient to avoid the need for
preparation of the orthoester derived carbenoid precursors. As both the introduction of the
diethoxymethyl group itself and the cyclopropanation reaction are carried out in the presence
of Lewis acids, we decided to investigate whether the two processes could be combined into a
one-pot reaction (Scheme 6). Thus, triethyl orthoformate was added dropwise to a mixture of
alkene 18, oxazolidinone 7, zinc, copper chloride, chlorotrimethylsilane and zinc chloride and
to our delight, the amidocyclopropane was obtained directly in 33% yield, comparable to the
38% overall yield obtained in the separate steps described above. Although, the
alkoxycyclopropanation of alkenes with orthoformates proceeds under similar conditions,10
no alkoxycyclopropane was observed, implying that the reaction between the amide and
orthoester is overwhelmingly favoured. We are currently optimising this new approach and
investigating its scope for the direct preparation of amidocyclopropanes from a wide range of
amide precursors.
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Scheme 6
a. 7, (EtO)3CH, Me3SiCl, ZnCl2, Zn, CuCl, Et2O, 33%.
In summary, the amidocyclopropanation of alkenes using dialkoxymethylamides as zinc
carbenoid precursors constitutes an effective method for functionalised cyclopropane
preparation, and enables a range of highly functionalised aminocyclopropane derivatives to be
accessed, which cannot readily be obtained using existing methods. These amidocyclopropane
units can be readily elaborated into cyclopropyl containing aminoalcohol or aminoacid motifs.
Acknowledgments
We would like to thank AstraZeneca for providing a studentship (to GB), and the EPSRC for
providing both a studentship (to LJ) and a postdoctoral fellowship (to TDS). We would also
like to thank Dr Abil Aliev for providing advice and assistance with NMR spectroscopy.
Experimental
All reactions were carried out in oven-dried glassware under a nitrogen atmosphere unless
otherwise indicated. Diethyl ether, tetrahydrofuran, toluene and dichloromethane were used
following purification from an anhydrous engineering zeolite drying apparatus. Methanol and
ethanol were distilled from magnesium turnings and iodine. Anhydrous dimethylformamide
was obtained from the Aldrich chemical company. Triethylamine was distilled from
potassium hydroxide before use. Chlorotrimethylsilane was distilled from calcium hydride
immediately prior to use. Styrene, cyclohexene, indene, 1,2-dihydronaphthalene and 3-carene
were distilled before use. All other chemicals were used as supplied unless otherwise
indicated. Column chromatography was carried out using BDH (40-60 µm) silica gel and
analytical thin layer chromatography was carried out using Merck Keiselgel aluminium-
backed plates coated with silica gel. Components were visualised using combinations of ultra-
violet lights, iodine, ceric ammonium molybdate, phosphomolybdic acid and potassium
permanganate. Melting points were determined using a Reichert hot-stage apparatus and are
uncorrected. Optical rotations were measured using a Perkin-Elmer 241 (sodium D-line, 529
nm) polarimeter and []
D
values are given in 10-1 deg cm2 g-1, concentration (c) in g per 100
mL. Infrared (IR) spectra were recorded on a Perkin-Elmer 1605 Fourier transform
spectrometer, and were recorded as thin films (NaCl plate). 1H NMR spectra were recorded at
300 MHz on a Bruker AMX300 spectrometer, at 400 MHz on a Bruker AMX400
spectrometer or at 500 MHz on a Bruker Avance 500 spectrometer in the stated solvent using
residual protic solvent CHCl3 ( = 7.26 ppm, s), DMSO ( = 2.56 ppm, qn) or D2O (4.79, s)
as the internal standard. Chemical shifts are quoted in ppm using the following abbreviations:
s, singlet; d, doublet; t, triplet; q, quartet; qn, quintet; m, multiplet; br, broad or a combination
of these. The coupling constants (J) are measured in Hertz. 13C NMR spectra were recorded at
75 MHz on a Bruker AMX300 spectrometer, at 100 MHz on a Bruker AMX400 spectrometer
or at 125 MHz on a Bruker Avance 500 spectrometer in the stated solvent using the central
reference of CHCl3 ( = 77.0 ppm, t), DMSO ( = 39.52 ppm, septet) as the internal standard.
Chemical shifts are reported to the nearest 0.1 ppm. Mass spectra and elemental analysis were
performed at the Department of Chemistry, University College London.
2,3-Dihydro-1-isoindolinone 914
Tin powder (41.7 g, 0.35 mol, 2.6 eq) was added to a vigorously stirred suspension of
phthalimide (20 g, 0.14 mol, 1 eq) in a mixture of glacial acetic acid (100 mL) and
concentrated hydrochloric acid (50 mL). The reaction mixture was heated at reflux for 2 h and
then filtered hot. The filtrate was concentrated and the residue partitioned between
dichloromethane (300 mL) and water (150 mL). The organic layer was separated and the
aqueous layer extracted with dichloromethane (2 x 50 mL). The combined organic extracts
were dried (MgSO4), filtered and concentrated. The crude product was purified twice by flash
column chromatography (EtOAc) and then triturated in toluene to give the lactam 9 (4.2 g,
Ph
a
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31.5 mmol, 23%) as a white solid; Mp 149-150 °C (lit. 150-151 °C14); IR (CH2Cl2): max 3214
(br s), 1658 (s) cm-1; 1H NMR (400 MHz, CDCl3):  4.48 (s, 2H, CH2), 7.18 (br s, 1H, NH),
7.47-7.60 (m, 4H, Ar-H); 13C NMR (100 MHz, CDCl3):  45.8, 123.2, 123.6, 128.0, 131.7,
132.6, 143.7, 172.6.
General procedure for synthesis of diethoxymethylamides 12-17
A mixture of amide (6.7 mmol), aluminium chloride (1.0 mmol, 0.15 eq) and triethyl
orthoformate (22 mL, 0.13 mol, 20 eq) was heated at 155°C for 24-72 h. The reaction mixture
was allowed to cool to room temperature and then quenched with saturated aqueous sodium
bicarbonate (25 mL). The aqueous phase was extracted with diethyl ether (50 mL then 2 x 25
mL) and the combined organic extracts were washed with brine (25 mL), dried (Na2SO4),
filtered and concentrated. The crude product was purified by flash column chromatography.
N-Diethoxymethylpyrrolidin-2-one 12 (alternative procedure)
Chlorotrimethylsilane (1.5 mL, 11.7 mmol) was added dropwise to a stirred solution of
pyrrolidinone (10g, 117.6 mmol), triethyl orthoformate (50 mL, 300.6 mmol) and
triphenylphosphine (50 mg, 0.2 mmol) in dichloromethane (200 mL) under nitrogen. The
resulting solution was stirred overnight at room temperature then poured into water (70 mL)
and saturated sodium bicarbonate (50 mL). The layers were separated and the organic layer
washed with brine (50 mL), dried (Na2SO4) and concentrated. The residue was distilled under
reduced pressure to give 12 as a colourless liquid (bp 101-103 °C at 3 mbar [lit. 84-86 °C at 1
mmHg17], 13.42 g, 61%).
N-Diethoxymethyl-2-oxazolidinone 13 (alternative procedure)
Acetyl chloride (1 mL, 14 mmol) was added to a stirred suspension of oxazolidin-2-one (10 g,
113.8 mmol) in triethyl orthoformate (50 mL, 300.6 mmol). The suspension was stirred
overnight at room temperature and then the reaction mixture was distilled under reduced
pressure to give diethoxymethyloxazoldinone as a colourless liquid (120-122 °C at 0.9
mmHg, 12.9 g, 60%).
N-Diethoxymethylpyrrolidin-2-one 12
Pale yellow oil; IR (film): max 2977 (s), 2897 (m), 1693 (s) cm-1; 1H NMR (300 MHz,
CDCl3):  1.20 (t, J=7.0, 6H, 2 × Me), 1.96-2.03 (m, 2H, CH2CH2N), 2.41 (t, J=8.2, 2H,
CH2CON), 3.42 (t, J=7.3, CH2N), 3.48 (dq, J=9.4, 7.0, 2H, 2 × CHHMe), 3.62 (dq, J=9.4,
7.0, 2H, 2 × CHHMe), 5.87 (s, 1H, CH); 13C NMR (75 MHz, CDCl3):  14.5, 17.8, 31.4, 40.5,
61.9, 98.8, 175.2; MS (FAB) m/z (%): 210 (M+Na, 100), 142 (25); HMRS: M+Na, found
210.11009. C9H17NO3Na requires 210.11061.
N-Diethoxymethyl-2-oxazolidinone 13
Pale yellow oil; IR (film): max 2979 (w), 2904 (w), 1747 (s) cm-1; 1H NMR (400 MHz,
CDCl3):  1.25 (t, J=7.1, 6H, Me), 3.53-3.73 (m, 6H, CH2N and 2 × CH2Me), 4.39 (t, J=8.2,
2H, CH2CH2N), 5.74 (s, 1H, CH); 13C NMR (100 MHz, CDCl3):  14.8, 38.6, 62.6, 62.8,
101.3, 157.4; MS (CI+) m/z (%): 190 (M+H, 2), 144, 100), 116 (12), 103 (100), 75 (14), 44
(16); HMRS: M+H, found 190.10785. C8H16NO4 requires 190.10793.
N-Diethoxymethylphthalimide 14
White solid; Mp 73-74 °C (lit., 73 °C18); IR (film): max 2977 (w), 1774 (m), 1720 (s), 1694
(w), 1469 (w) cm-1; 1H NMR (300 MHz, CDCl3):  1.25 (t, J=7.1, 6H, 2 x CH3), 3.62 (dq,
J=9.4, 7.1, 2H, 2 × CHHMe), 3.77 (dq, J=9.4, 7.1, 2H, 2 × CHHMe), 6.09 (s, 1H, CH), 7.68-
7.77 (m, 2H, Ar-H), 7.82-7.90 (m, 2H, Ar-H); 13C NMR (75 MHz, CDCl3):  14.8, 63.4, 99.8,
123.6, 131.7, 134.3, 166.6; MS (CI+) m/z (%): 249 (M+, 100), 175 (56), 147 (78); HMRS: M+,
found 249.09952. C13H15NO4 requires 249.1001.
2-Diethoxymethyl-2,3-dihydro-1-isoindolinone 15
Brown oil; IR (film): max 2977 (m), 2932 (w), 1694 (s), 1620 (w), 1470 (m), 1452 (w) cm-1;1H NMR (400 MHz, CDCl3):  1.25 (t, J=7.0, 6H, 2 × Me), 3.57 (dq, J=9.5, 7.0, 2H, 2 ×
CHHCH3), 3.74 (dq, J=9.5, 7.0, 2H, 2 × CHHCH3), 4.49 (s, 2H, CH2N), 6.23 (s, 1H, CH),
7.45-7.51 (m, 2H, Ar-H), 7.58 (t, J=7.5, 1H, Ar-H), 7.87 (d, J=7.5, 1H, Ar-H); 13C NMR (100
MHz, CDCl3):  14.8, 44.2, 62.5, 99.2, 123.2, 124.1, 128.0, 132.0, 132.1, 142.0, 168.9; MS
(CI+) m/z (%): 236 (M+H, 6), 190 (44), 134 (59), 103 (46); HMRS: M+H, found 236.12847.
C13H18NO3 requires 236.12866.
3-(Diethoxymethyl)benzoxazolin-2-one 16
Red oil; IR (film): max 2980, 1786 (s), 1625 (w); 1H NMR (400 MHz, DMSO):  1.16 (t,
J=7.1, 6H, 2 × Me), 3.60 (dq, J=9.6, 7.1, 2H, 2 × CHHMe), 3.73 (dq, J=9.6, 7.1, 2H, 2 ×
CHHMe), 6.11 (s, 1H, CH), 7.16-7.24 (m, 2H, Ar), 7.34-7.39 (m, 2H, Ar); 13C NMR: (100
MHz, DMSO) 14.6, 62.4, 101.4, 110.0, 111.9, 122.9, 124.2, 127.7, 141.9, 152.4. MS (CI+)
m/z (%): 237 (M+, 70), 205 (75), 193 (100), 104 (70); HRMS: M+H, found: 238.10832.
C12H16NO4 requires 238.10793.
N-Benzyl-N-diethoxymethylacetamide 17
Yellow oil; IR (film): max 2978 (m), 2933 (w), 1670 (s), 1497 (w) cm-1; 1H NMR (400 MHz,
353 K, DMSO):  1.10 (t, J=7.1, 6H, 2 × Me), 2.05 (s, 2.1H, COCH3), 2.98 (s, 0.9H,
COCH3), 3.37-3.63 (m, 4H, 2 × CH2CH3), 4.41 (s, 0.6H, PhCH2N), 4.50 (s, 1.4H, PhCH2N),
5.58 (br s, 0.3H, CH), 6.00 (br s, 0.7H, CH), 7.16-7.35 (m, 5H, Ar-H); 13C NMR (major
rotamer, 100 MHz, 353 K, DMSO):  14.0, 21.4, 43.7, 61.2, 102.2, 125.8, 126.7, 127.3,
138.9, 169.0; MS (CI+) m/z (%): 252 (M+H, 3), 206 (62), 150 (100), 103 (61), 91 (68);
HMRS: M+H, found 252.16019. C14H22NO3 requires 252.15997.
Benzyldimethyl(vinyl)silane 29
A solution of benzyl chloride (1.15 mL, 10 mmol) in dry diethyl ether (10 mL) was added
dropwise to a mixture of magnesium turnings (0.24 g, 10 mmol) and iodine (2 crystals) in dry
diethyl ether (10 mL) under nitrogen. The reaction mixture was stirred for 1 h and
dimethylvinylchlorosilane (1.64 mL, 12 mmol) was added dropwise. The reaction mixture
was heated at reflux for 16 h and then quenched carefully with saturated aqueous ammonium
chloride (20 mL). The organic layer was separated and the aqueous layer was extracted with
diethyl ether (2 x 20 mL). The combined organic extracts were dried (MgSO4), filtered and
concentrated in vacuo. The crude product was purified by flash column chromatography
(Petrol) to give 29 as a colourless oil (1.09 g, 62%); IR (CDCl3): max 3024, 2957, 2893 (w),
1601, 1493 (s), 1452 (w), 1404 cm-1; 1H NMR (500 MHz, CDCl3):  0.57 (s, 6H, 2 × Me),
2.15 (s, 2H, CH2), 5.67 (dd, J=20.3, 3.8, 1H, CH=CHH), 5.97 (dd, J=14.7, 3.8, 1H,
CH=CHH), 6.13 (dd, J=20.3, 14.7, 1H, CH=CH2), 6.99-7.02 (m, 2H, Ar-H), 7.05-7.09 (m,
1H, Ar-H), 7.18-7.23 (m, 2H, Ar-H); 13C NMR (125 MHz, CDCl3):  −3.7, 25.8, 124.0, 
128.1, 128.2, 132.2, 138.2, 139.9; MS (EI) m/z (%): 176 (M+, 13), 91 (17), 85 (100); HMRS:
M+, found 176.10155. C11H16Si requires 176.10158.
Ethyl 2-allyloxyacetate 3319
Sodium hydride (60% dispersion in mineral oil, 1.76 g, 44 mmol) was added portionwise to a
solution of ethyl glycolate (4.16 g, 40 mmol) in anhydrous DMF (20 mL) under nitrogen at 0
°C. After stirring for 30 minutes, allyl bromide (3.8 mL, 44 mmol) was added dropwise and
the reaction mixture was allowed to warm to room temperature. After stirring for 90 min at
room temperature, water (20 mL) was added and the reaction mixture extracted with ether (3
× 30 mL). The combined organic layers were washed with brine, dried (MgSO4) and
concentrated and the residue was distilled to afford two fractions: Fraction 1 (bp 52-54 °C, 14
mbar) contained a mixture of the alkene 33 and DMF (2:1 ratio), Fraction 2 (bp 64-65 °C, 10
mbar, lit. 70-74 °C at 20 mmHg19) contained the alkene 33. The two fractions were combined
and dissolved in ether (30 mL) and washed with saturated lithium chloride (2 × 20 mL), dried
(MgSO4), and concentrated to give the alkene as a colourless liquid (1.37 g, 9.5 mmol, 24%);
IR (film): max 2984, 2941, 2909, 2876, 1755 (s) cm-1; 1H NMR (500 MHz, CDCl3):  1.29 (t,
J=7.2, 3H, Me), 4.07 (s, 2H, CH2O), 4.10 (dt, J=5.8, 1.5, 2H, CH2CH), 4.22 (q, J=7.2,
CH2Me), 5.26 (dq, J=10.3, 1.5, 1H, CHH=CH), 5.33 (dd, J=17.1, 1.5, CHH=CH), 5.93 (ddt,
J=17.1, 10.3, 5.8, CH=CHH); 13C NMR (100 MHz, CDCl3):  14.1, 60.8, 67.1, 72.3, 118.2,
133.6, 170.3.
Ethyl 2-(cyclopent-2-enyl)acetate 3520
Acetyl chloride (3 mL, 42.4 mmol ) was added dropwise to a solution of ethanol (30 mL) at 0
°C. 2-(Cyclopent-2-enyl)acetic acid (2 g, 15.9 mmol) was added dropwise to the solution at 0
°C. The resulting mixture was allowed to warm to room temperature and was then heated to
reflux for 4 hours. After concentration under reduced pressure the residue was dissolved in
chloroform and concentrated under reduced pressure again to give a biphasic mixture. The
mixture was extracted with dichloromethane (10 mL) and the combined organic layers were
dried over MgSO4 and concentrated under reduced pressure. The crude product was purified
by flash chromatography (petrol:ether, 4:1) to give the ester as a pale yellow oil (1.6 g, 65 %);
IR (film): max 2907 (s), 1732 (s), 1614 (w), 1259 (s), 1148 (s), 1032 (s) cm-1; 1H NMR (500
MHz, CDCl3):  1.26 (t, J=7.2, 3H, CH3), 1.42-1.50 (m, 1H, CHHCHCH2), 2.07-2.16 (m, 1H,
CHHCHCH2), 2.25-2.33 (m, 2H, CH2C=O), 2.33-2.42 (m, 2H, CH2CH=CH), 3.04-3.12 (m,
1H, CHCH=CH), 4.14 (q, J=7.2, 2H, CH2CH3), 5.65-5.68 (m, 1H, CH=CH), 5.74-5.78 (m,
1H, CH=CH); 13C NMR (125 MHz, CDCl3):  14.3, 29.6, 31.8, 40.5, 41.8, 60.2, 131.4, 133.7,
173.0; MS (EI) m/z (%): 153 (M-H, 33), 79 (75), 57 (100); HMRS: M-H, found 153.09115.
C9H13O2 requires 153.09101.
(E)-Ethyl 3,7-dimethylocta-2,6-dienoate 3821
Sodium hydride (60 % mineral oil dispersion, 0.312 g, 7.80 mmol) was washed three times
with hexane under nitrogen. The resulting solid was suspended in dry THF (10 mL) cooled to
0 °C. A solution of triethyl phosphonoacetate (1.75 g, 7.8 mmol) in tetrahydrofuran (6 mL)
was added with stirring at 0 °C, and the mixture was stirred at this temperature for a further
30 min. A solution of 6-methyl-5-hepten-2-one (0.74 g, 5.9 mmol) in tetrahydrofuran (5 mL)
was added and the resulting mixture was stirred at 0 °C for 1 hour and then allowed to warm
to room temperature and stirred for 16 hours. The residue was then poured into a mixture of
ether (50 mL) and a saturated aqueous ammonium chloride (20 mL). The ether layer was
separated and the aqueous layer extracted with ether (2 × 20 mL). The combined organic
layers were dried over MgSO4 and concentrated under reduced pressure. The crude product
(approximately 75:25 E:Z) was purified by column chromatography (3 % tBuOMe in hexane)
to give 1.03 g of a mixture of (E) and (Z) isomers as a colourless oil and 187 mg of the pure E
isomer as a colourless oil (89% overall yield). The pure E isomer was used in the
cyclopropanation reaction; IR (film): max 1643 (s), 1385 (w), 1223 (w), 1142 cm-1; 1H NMR
(400 MHz, CDCl3):  1.28 (t, J=7.1, 3H, CH3CH2), 1.60 (s, 3H, CH3CCH3), 1.68 (s, 3H,
CH3CCH3) 2.15 (s, 3H, CH3C=CH), 2.16 (m, 4H, 2 × CH2), 4.15 (q, J=7.1, 2H, CH2CH3),
5.03-5.1 (m, 1H, CHCOO), 5.66 (br s, 1H, Me2C=CH); 13C NMR (125 MHz, CDCl3):  14.3,
17.7, 18.8, 25.7, 26.0, 40.9, 59.5, 115.6, 123.0, 132.5, 159.8, 166.9; MS (EI) m/z (%): 196
(M+,10), 151 (33), 123 (60), 97 (52), 83 (100); HRMS: M+, found 196.14572. C12H20O2
requires 196.14632.
Preparation of Zinc amalgam
Zinc dust (10.0 g, 153 mmol) was added portionwise to a vigorously stirred solution of
mercury (II) chloride (2.0 g, 7.20 mmol) in concentrated hydrochloric acid (2 mL) and water
(30 mL). The suspension was stirred for 10 min and then filtered and the zinc amalgam
washed with water (3 × 20 mL), acetone (3 × 20 mL), ethanol (3 × 20 mL) and ether (3 × 20
mL) and then dried under vacuum.
Zinc dust for cyclopropanation reactions
A suspension of commerically available zinc dust (5 g, 76.5 mmol) in 2% hydrochloric acid
(15 mL) was stirred for 10 min and then filtered and the collected zinc dust washed with
water (3 × 20 mL), acetone (3 × 20 mL), ethanol (3 × 20 mL) and ether (3 × 20 mL) and then
dried under vacuum.
General procedure for the cyclopropanation of alkenes using Zinc amalgam
A solution of diethoxymethylamide (2.11 mmol) in dry diethyl ether (3 mL) was added via a
motorised syringe pump over 4-6 h to a vigorously stirred mixture of zinc amalgam (1.38 g,
21.1 mmol), zinc chloride (1.0 M solution in diethyl ether, 2.11 mL, 2.11 mmol),
chlorotrimethylsilane (1.34 mL, 10.56 mmol) and alkene (1.06 mmol) in dry diethyl ether (5.5
mL) under nitrogen at reflux. The mixture was stirred at reflux overnight and then allowed to
cool to room temperature. The reaction was quenched with saturated aqueous sodium
bicarbonate solution (20 mL) and after stirring for 20 min, the mixture was filtered through
celite and the separated zinc washed with diethyl ether (20 mL) and dichloromethane (20
mL). The organic solvents were removed in vacuo and the aqueous layer was extracted with
diethyl ether (3 x 20 mL). The combined organic extracts were washed with brine (20 mL),
dried (MgSO4), filtered and concentrated in vacuo. The crude product was then purified by
flash column chromatography to give the amidocyclopropane(s).
General procedure for cyclopropanation of alkenes using Zn/CuCl
A solution of diethoxymethylamide (2.12 mmol) in diethyl ether (3 mL) was added dropwise
via syringe pump (0.6 mLh-1) to a vigorously stirred refluxing mixture of zinc dust (1.4 g,
21.5 mmol), copper (I) chloride (140 mg, 1.4 mmol), zinc chloride (1.0 M solution in Et2O, 1
mL, 1 mmol), alkene (1.06 mmol) and chlorotrimethlysilane (1.4 mL, 11 mmol) in diethyl
ether (5 mL). The reaction mixture was refluxed overnight, then quenched by addition of
saturated sodium bicarbonate solution (4 mL), and filtered, washing the resulting solids with
ether (10 mL). The biphasic mixture was extracted with ether (3 × 20 mL) and the combined
organic layers washed with brine (30 mL), dried (MgSO4) and concentrated. The residue was
purified by column chromatography to give the amidocyclopropane.
General procedure for cyclopropanation of alkenes without TMSCl.
A solution of diethoxymethylamide (2.12 mmol) in diethyl ether (2 mL) was added dropwise
via syringe pump (0.6 mLh-1) to a vigorously stirred refluxing mixture of zinc dust (1.4 g,
21.5 mmol), copper (I) chloride (140 mg, 1.4 mmol), zinc chloride (1.0M solution in Et2O,
5.4 mL, 5.4 mmol), alkene (1.06 mmol) in diethyl ether (1 mL). The reaction mixture was
refluxed overnight, then quenched by addition of saturated sodium bicarbonate solution (4
mL), and filtered, washing the resulting solids with ether (10 mL). The biphasic mixture was
extracted with ether (3 × 20 mL) and the combined organic layers washed with brine (30 mL),
dried (MgSO4) and concentrated. The residue was purified by column chromatography to give
the amidocyclopropane.
Procedure for cyclopropanation of allyl benzene using oxazolidinone 7 and
triethylorthoformate
Zinc chloride (1.0 M solution in Et2O, 2.7 mL, 2.70 mmol) and chlorotrimethylsilane (2.45
mL, 18.9 mmol) were added to a suspension of oxazolidinone (238 mg, 2.70 mmol) in ether
(5 mL) and the solution heated to reflux for 10 min. Zinc dust (1.32 g, 20.3 mmol) and copper
(I) chloride (132 mg, 1.32 mmol) were added followed by a solution of allyl benzene (165
mg, 1.39 mmol) in ether (2 mL). The reaction mixture was then heated to reflux and triethyl
orthoformate (2.3 mL, 13.5 mmol) was added dropwise via syringe pump (0.25 mLh-1). After
heating under reflux overnight, saturated sodium bicarbonate solution (4 mL) was added and
the resulting suspension was filtered, washing the solids with ether (10 mL). The biphasic
mixture was extracted with ether (3 × 20 mL) and the combined organic layers washed with
brine (30 mL), dried (MgSO4) and concentrated. The residue was purified by column
chromatography to give the amidocyclopropane 56 as a colourless oil (100 mg, 0.46 mmol,
33%).
1-(2-Benzylcyclopropyl)-2-pyrrolidinone (trans and cis) 39
Colourless oil; IR (mixture of trans and cis, film): max 2992, 2958, 1688 (s), 1495, 1454,
1421 (s) cm-1; 1H NMR (trans, 500 MHz, CDCl3):  0.75 (ddd, J=7.5, 6.1, 5.8, 1H,
CHHCHN), 0.95 (ddd, J=9.4, 5.8, 4.1, 1H, CHHCHN), 1.28 (dtdd, J=9.4, 6.8, 6.1, 3.5, 1H,
CHCHN), 1.86-1.93 (m, 2H, CH2CH2N), 2.32 (t, J=8.0, 2H, CH2CO), 2.50-2.55 (m, 2H,
CHN and CHHAr), 2.70 (dd, J=14.7, 6.8, 1H, CHHAr), 3.16 (t, J=7.0, 2H, CH2N), 7.18-7.30
(m, 5H, Ar-H); 13C NMR (trans, 125 MHz, CDCl3):  12.1, 17.8, 19.0, 31.6, 31.6, 38.0, 47.2,
125.9, 128.2, 140.5, 175.8; 1H NMR (cis, 500 MHz, CDCl3):  0.71 (ddd, J=6.4, 6.0, 4.6, 1H,
CHHCHN), 1.00 (ddd, J=8.9, 8.0, 6.0, 1H, CHHCHN), 1.34 (tddd, J=8.9, 7.1, 6.4, 4.9, 1H,
CHCHN), 1.94-2.01 (m, 2H, CH2CH2N), 2.19 (dd, J=14.4, 8.9, 1H, CHHAr), 2.38-2.42 (m,
2H, CH2CO), 2.66 (ddd, J=8.0, 7.1, 4.6, 1H, CHN), 3.02 (dd, J=14.4, 4.9, 1H, CHHAr), 3.29-
3.39 (m, 2H, CH2N), 7.18-7.30 (m, 5H, Ar-H); 13C NMR (cis, 125 MHz, CDCl3):  10.3,
18.2, 18.5, 30.4, 31.6, 33.8, 49.1, 125.8, 128.2, 141.1, 176.9; MS (FAB) m/z (%): 216 (M+H,
100), 124 (, 63), 91 (29); HMRS: M+, found 215.13149. C14H17NO requires 215.1310.
1-(2-Phenylcyclopropyl)-2-pyrrolidinone (trans and cis) 40
Colourless oil; IR (mixture of trans and cis, film): max 2980 (s), 2886 (s), 1680 (s), 1499,
1459 cm-1; 1H NMR (trans, 500 MHz, CDCl3):  1.28 (dt, J=7.7, 6.3, 1H, CHHCHN), 1.39
(ddd, J=9.8, 6.3, 4.6, 1H, CHHCHN), 1.96-2.03 (m, 2H, CH2CH2N), 2.17 (ddd, J=9.9, 6.3,
3.6, 1H, CHCHN), 2.39 (t, J=8.1, 2H, CH2CO), 2.78 (ddd, J=7.7, 4.6, 3.6, 1H, CHN), 3.35-
3.40 (m, 2H, CH2N), 7.10-7.19 (m, 3H, Ar-H), 7.22-7.28 (m, 2H, Ar-H); 13C NMR (trans,
125 MHz, CDCl3):  14.7, 18.1, 22.7, 31.8, 34.9, 47.5, 126.1, 126.4, 128.4, 140.4, 175.9; 1H
NMR (cis, 500 MHz, CDCl3):  1.37 (ddd, J=9.1, 7.8, 6.8, 1H, CHHCHN), 1.45-1.53 (m, 1H,
CHHCH2N), 1.56-1.65 (m, 2H, CHHCHNand CHHCH2N), 2.10-2.22 (m, 3H, CHCHN and
CH2CO), 2.64 (ddd, J=9.5, 8.5, 4.8, 1H, CHHN), 2.79 (td, J=7.8, 4.9, 1H, CHN), 2.85 (ddd,
J=9.5, 8.0, 6.8, 1H, CHHN), 7.07-7.14 (m, 3H, Ar-H), 7.17-7.21 (m, 2H, Ar-H); 13C NMR
(cis, 125 MHz, CDCl3):  10.7, 18.0, 21.7, 31.5, 32.4, 48.0, 126.1, 127.8, 127.9, 136.8, 176.7;
MS (EI) m/z (%): 201 (M+, 7), 172 (21), 144 (24), 130 (69), 115 (100), 103 (72), 91 (52), 77
(74); HMRS: M+, found 201.11549. C13H15NO requires 201.11482.
trans-1-(2-tert-Butylcyclopropyl)-2-pyrrolidinone 41
Colourless oil; IR (film): max 2955 (s), 2868, 1694 (s), 1462, 1421 (s) cm-1; 1H NMR (trans,
500 MHz, CDCl3):  0.67-0.74 (m, 2H, CH2CHN), 0.81 (s, 9H, C(CH3)3), 0.86 (ddd, J=9.9,
6.8, 4.1, 1H, CHCHN), 1.84-1.94 (m, 2H, CH2CH2N), 2.29 (t, J=8.2, 2H, CH2CO), 2.47 (dt,
J=7.5, 4.1, 1H, CHN), 3.26 (t, J=7.1, 2H, CH2N); 13C NMR (trans, 125 MHz, CDCl3):  8.7,
17.9, 28.1, 28.1, 29.0, 29.5, 31.8, 47.5, 175.8; MS (EI) m/z (%): 181 (M+, 20), 166 (10), 124
(100), 96 (29), 81 (23), 69 (14), 57 (12); HMRS: M+, found 181.146380. C11H19NO requires
181.146655.
(±)-1-((2S,3S)-2,3-Dibutylcyclopropyl)pyrrolidin-2-one 42
Colourless oil; IR (film): max 2954 (s), 2924 (s), 2856, 1694 (s), 1416 cm-1; 1H NMR (500
MHz, CDCl3):  0.68-0.79 (m, 3H), 0.82 (t, J=7.0, 3H, Me), 0.83 (t, J=7.0, 3H, CH3), 1.14-
1.36 (m, 10H), 1.45-1.53 (m, 1H), 1.87-1.96 (m, 2H, CH2CH2N), 2.25 (dd, J=6.4, 4.2, 1H,
CHN), 2.32 (t, J=8.0, 2H, CH2CO), 3.20-3.31 (m, 2H, CH2N); 13C NMR (125 MHz, CDCl3):
 13.9, 14.0, 18.8, 22.4, 22.5, 24.1, 25.5, 27.5, 31.0, 31.6, 31.6, 32.5, 36.6, 49.0, 176.6; MS
(EI) m/z (%): 237 (M+, 43), 194 (21), 180 (100), 138 (15), 124 (35), 98 (53), 86 (35), 67 (13),
55 (15); HMRS: M+, found 237.2084. C15H27NO requires 237.20925.
(±)-1-((1R,2R,3S)-2,3-Dibutylcyclopropyl)pyrrolidin-2-one and (±)-1-((1S,2R,3S)-2,3-
Dibutylcyclopropyl)pyrrolidin-2-one 43
Colourless oil; IR (mixture of trans and cis, film): max 2956 (s), 2929 (s), 2857, 1699 (s),
1464, 1417 cm-1; 1H NMR (trans, 400 MHz, CDCl3):  0.88 (t, J=7.1, 6H, 2 × Me), 0.98-1.02
(m, 2H, 2 × CHBu), 1.22-1.50 (m, 12H, 6 × CH2), 1.98 (tt, J=8.1, 7.0, 2H, CH2CH2N), 2.01
(t, J=3.8, 1H, CHN), 2.32 (t, J=8.1, 2H, CH2CO), 3.25 (t, J=7.0, 2H, CH2N); 13C NMR (trans,
100 MHz, CDCl3):  14.1, 18.0, 22.6, 23.5, 23.5, 26.8, 31.8, 37.8, 47.4, 175.6; 1H NMR (cis,
400 MHz, CDCl3):  0.88 (t, J=7.2, 6H, 2 × Me), 0.91-0.98 (m, 2H, 2 × CHBu), 1.16-1.51 (m,
12H, 6 × CH2), 1.98 (tt, J=8.2, 7.7, 2H, CH2CH2N), 2.31 (t, J=8.2, 2H, CH2CO), 2.38 (t,
J=7.7, 1H, CHN), 3.25 (t, J=7.0, 2H, CH2N); 13C NMR (cis, 100 MHz, CDCl3):  14.1, 18.9,
19.8, 22.9, 23.4, 31.0, 32.4, 33.4, 48.8, 178.5; MS (EI) m/z (%): 238 (M+H, 100), 194 (25),
180 (95), 138 (13), 124 (43), 98 (73), 86 (43), 67 (10), 55 (13), 41 (34); HMRS: M+, found
237.20916. C15H27NO requires 237.20925.
1-Bicyclo[4.1.0]hept-7-yl-2-pyrrolidinone (exo and endo) 44
Colourless oil; IR (mixture of exo and endo, film): max 2927 (s), 2853 (s), 1682 (s), 1418 (s)
cm-1; 1H NMR (exo, 500 MHz, C6D6):  0.93-1.00 (m, 2H), 1.03-1.11 (m, 4H), 1.21 (tt, J=8.0,
7.0, 2H, CH2CH2N), 1.65-1.79 (m, 4H), 1.97 (t, J=8.0, 2H, CH2CO), 2.22 (t, J=3.7, 1H,
CHN), 2.57 (t, J=7.0, 2H, CH2N); 13C NMR (exo, 125 MHz, C6D6):  17.2, 18.1, 21.6, 22.7,
31.6, 36.9, 46.4, 174.4; 1H NMR (endo, 500 MHz, C6D6):  0.87-0.92 (m, 2H, 2 × CHCHN),
0.93-1.13 (m, 4H), 1.29 (tt, J=7.9, 6.9, 2H, CH2CH2N), 1.65-1.79 (m, 4H); 1.93 (t, J=7.9, 2H,
CH2CO), 2.04 (t, J=7.7, 1H, CHN), 2.79 (t, J=6.9, 2H, CH2N); 13C NMR (endo, 125 MHz,
C6D6):  13.0, 18.9, 20.2, 22.5, 30.9, 34.0, 48.0, 176.7; MS (EI) m/z (%): 179 (M+, 100), 150
(32), 136 (15), 124 (20), 108 (10), 98 (32), 94 (30), 79 (19), 72 (30), 59 (57), 55 (48); HMRS:
M+, found 179.13102. C11H17NO requires 179.1310.
1-(1-Methylbicyclo[4.1.0]hept-7-yl)-2-pyrrolidinone (exo and endo) 45
Colourless oil; IR (mixture of exo and endo, film): max 2929 (s), 2861, 1693 (s), 1492 (w),
1412 cm-1; 1H NMR (mixture of exo and endo, 500 MHz, C6D6):  0.73 (td, J=7.9, 2.6, 1H,
CHCHN), 0.90 (ddd, J=7.5, 4.1, 1.7, 1H, CHCHN), 0.96-1.22 (m, 14H), 1.27-1.35 (m, 4H,
CH2CH2N), 1.47-1.66 (m, 4H), 1.75-1.90 (m, 5H), 1.91-1.96 (m, 2H), 1.98-2.03 (m, 2H), 2.09
(d, J=4.2, 1H, CHN), 2.66 (dt, J=9.3, 7.0, 1H), 2.68 (dt, J=9.3, 7.0, 1H), 2.78 (dt, J=9.3, 7.0,
1H), 2.80 (dt, J=9.3, 6.3, 1H); 13C NMR (mixture of exo and endo, 125 MHz, C6D6):  18.2,
18.6, 19.0, 20.4, 21.6, 21.7, 21.7, 21.9, 22.1, 22.3, 22.4, 23.2, 23.5, 27.8, 28.0, 30.5, 31.0,
31.4, 41.2, 41.4, 47.9, 48.1, 175.2, 176.6; MS (EI) m/z (%): 193 (M+, 67), 178 (45), 164 (20),
150 (15), 124 (10), 108 (83), 98 (53), 93 (55), 86 (100), 79 (18), 55 (14). HMRS: M+, found
193.14610. C12H19NO requires 193.14655.
2-Ethylhexyl-[2-(2-oxopyrrolidin-1-yl)-cyclopropyl] carboxylate (trans and cis) 46
Colourless oil; IR (diastereomeric mixture of trans and cis, film): max 2961 (s), 2934 (s),
2875, 2862, 1741 (s), 1698 (s), 1460 (s), 1420 (s) cm-1; 1H NMR (diastereomeric mixture of
trans cyclopropanes, 500 MHz, CDCl3):  0.74 (t, J=7.2, 12H, 4 × CH3), 1.05-1.21 (m, 10H),
1.22 (td, J=7.6, 5.5, 2H), 1.26-1.51 (m, 8H), 1.80-1.93 (m, 4H, 2 × CH2CH2N), 2.10 (tt,
J=8.8, 5.5, 2H, 2 × OCOCH), 2.22 (t, J=8.3, 4H, 2 × CH2CO), 2.57 (ddd, J=7.4, 5.3, 1.8, 2H,
2 × CHN), 3.26-3.38 (m, 4H, 2 × CH2N), 3.97 (ddd, J=7.4, 4.4, 1.8, 2H, 2 × CHOCO); 13C
NMR (diastereomeric mixture of trans cyclopropanes, 125 MHz, CDCl3):  11.5, 13.6, 17.8,
22.3, 25.0, 29.2, 31.1, 31.3, 46.6, 47.0, 51.7, 175.8, 176.2, 176.7; 1H NMR (diastereomeric
mixture of cis cyclopropanes, 300 MHz, CDCl3):  0.83 (t, J=7.3, 12H, 4 × CH3), 1.13-1.57
(m, 20H), 1.89-2.01 (m, 4H, 2 × CH2CH2N), 2.19 (tt, J=8.2, 5.6, 2H, 2 × OCOCH), 2.34 (t,
J=8.1, 4H, 2 × CH2CO), 2.65-2.70 (m, 2H, 2 × CHN), 3.26-3.43 (m, 4H, 2 × CH2N), 4.14 (td,
J=7.1, 4.1, 1H, 2 × CHOCO), 4.15 (td, J=7.1, 4.1, 1H, 2 × CHOCO); 13C NMR
(diastereomeric mixture of cis cyclopropanes, 125 MHz, CDCl3):  11.2, 11.6, 13.8, 18.3,
22.5, 25.0, 25.3, 28.7, 29.4, 31.3, 31.5, 31.6, 47.0, 48.1, 49.7, 176.3, 176.5; MS (EI) m/z (%):
268 (M+H, 49), 140 (99), 124 (32), 112 (87), 99 (28), 84 (11), 69 (42), 57 (100), 41 (73);
HMRS: M+H, found 268.19116. C15H26NO3 requires 268.19124.
2-Ethylhexyl-[1-methyl-2-(2-oxopyrrolidin-1-yl)-cyclopropyl] carboxylate (trans and cis)
47
Colourless oil; IR (diastereomeric mixture of trans and cis, film): max 2975 (s), 2931 (s),
2865, 1700 (s), 1459 (w), 1419 (w) cm-1; 1H NMR (diastereomeric mixture of trans and cis,
500 MHz, CDCl3):  0.85 (t, J=7.0, 24H, 8 × CH3), 1.04 (t, J=6.8, 2H), 1.18-1.35 (m, 46H),
1.49-1.56 (m, 4H, 4 × OCH2CH), 1.63 (dd, J=8.7, 5.8, 2H), 1.67-1.71 (m, 2H), 1.89-2.03 (m,
8H, 4 × CH2CH2N), 2.25-2.31 (m, 4H, 2 × CH2), 2.37 (t, J=8.4, 4H, 2 × CH2), 2.69 (t, J=6.8,
2H, 2 × CHN), 2.99 (dd, J=8.5, 5.7, 2H, 2 × CHN), 3.20-3.36 (m, 6H), 3.49 (dt, J=8.9, 7.5,
2H), 3.85-3.98 (m, 8H, 4 × OCH2CH); 13C NMR (diastereomeric mixture of trans and cis,
125 MHz, CDCl3):  10.9, 11.0, 13.3, 18.3, 18.4, 19.2, 20.5, 20.8, 22.9, 23.7, 23.8, 24.3, 26.2,
29.3, 30.3, 30.4, 38.6, 38.7, 40.4, 48.0, 48.9, 67.1, 67.2, 67.3, 172.2, 174.0, 176.4, 176.5; MS
(EI) m/z (%): 296 (M+H, 100), 183 (60), 165 (65), 138 (85), 98 (64), 71 (14), 57 (27), 41
(49); HMRS: M+H, found 296.22254. C17H30NO3 requires 296.22234.
[2-(2-Oxopyrrolidin-1-yl)-cyclopropyl] benzoate (trans and cis) 48
Colourless oil; IR (mixture of trans and cis, film): max 2961, 1726 (s), 1689 (s), 1615 (w),
1452, 1420 (s) cm-1; 1H NMR (trans, 500 MHz, CDCl3):  1.40-1.43 (m, 2H), 1.89-1.98 (m,
2H, CH2CH2N), 2.36 (t, J=8.4, 2H, CH2CO), 2.80 (ddd, J=7.8, 7.0, 5.4, 1H, CHN), 3.33-3.43
(m, 2H, CH2N), 4.44 (q, J=5.4, 1H, CHOCO), 7.38-7.42 (m, 2H, Ar-H), 7.51-7.56 (m, 1H,
Ar-H), 7.90-7.94 (m, 2H, Ar-H); 13C NMR (trans, 125 MHz, CDCl3):  11.2, 18.5, 29.0, 31.5,
48.2, 50.6, 128.4, 129.3, 129.3, 133.2, 166.8, 176.7; 1H NMR (cis, 500 MHz, CDCl3):  1.44-
1.48 (m, 2H, CH2CHN), 1.95-2.07 (m, 2H, CH2CH2N), 2.37 (t, J=8.4, 2H, CH2CO), 2.85
(ddd, J=9.0, 6.6, 1.8, 1H, CHN), 3.45-3.53 (m, 2H, CH2N), 4.33 (ddd, J=6.6, 5.4, 1.8, 1H,
CHO), 7.38-7.42 (m, 2H, Ar-H), 7.51-7.56 (m, 1H, Ar-H), 7.90-7.94 (m, 2H, Ar-H); 13C
NMR (cis, 125 MHz, CDCl3):  14.0, 18.5, 31.4, 31.6, 47.4, 52.6, 128.4, 129.3, 129.6, 133.3,
167.1, 176.2; MS (EI) m/z (%): 245 (M+, 74), 216 (24), 162 (61), 154 (22), 141 (86), 124
(100), 114 (100), 106 (89), 94 (87), 84 (90), 77 (86); HMRS: M+, found 245.10578.
C14H15NO3 requires 245.10519.
1-(2-Trimethylsilanylcyclopropyl)-2-pyrrolidinone 49
Colourless oil; IR (film): max 2954 (s), 2894, 1694 (s), 1419 (s) cm-1; 1H NMR (trans, 500
MHz, CDCl3):  −0.12 (ddd, J=11.3, 8.2, 5.3, 1H, CHSi), −0.06 (s, 9H, Si(CH3)3), 0.63 (ddd,
J=8.2, 6.5, 4.8, 1H, CHHCHN), 0.89 (ddd, J=11.3, 4.8, 3.6, 1H, CHHCHN), 1.84-1.94 (m,
2H, CH2CH2N), 2.31 (t, J=8.0, 2H, CH2CO), 2.50 (ddd, J=6.5, 5.3, 3.6, 1H, CHN), 3.18-3.22
(m, 2H, CH2N); 13C NMR (trans, 125 MHz, CDCl3):  −2.6, 4.2, 8.6, 18.0, 29.1, 31.2, 47.2, 
175.8; MS (EI) m/z (%): 197 (M+, 40), 182 (66), 168 (36), 154 (27), 142 (66), 124 (11), 73
(100), 59 (22); HMRS: M+, found 197.12332. C10H19NOSi requires 197.12355.
1-[2-(Benzyldimethylsilanyl)-cyclopropyl)]-2-pyrrolidinone 50
Colourless oil; IR (film): max 2953 (m), 2891 (w), 1689 (s), 1493 (m), 1419 (m) cm-1; 1H
NMR (500 MHz, CDCl3):  −0.10 (s, 3H, SiMe), −0.08 (ddd, J=11.3, 8.2, 5.3, 1H, CHSi),
−0.05 (s, 3H, SiMe), 0.64 (ddd, J=8.2, 6.7, 5.0, 1H, CHHCHN), 0.92 (ddd, J=11.3, 5.0, 3.7,
1H, CHHCHN), 1.87-1.95 (m, 2H, CH2CH2N), 2.13 (s, 2H, CH2Ph), 2.34 (t, J=8.0, 2H,
CH2CO), 2.61 (ddd, J=6.7, 5.3, 3.7, 1H, CHN), 3.16 (t, J=7.0, 2H, CH2N), 6.99-7.06 (m, 3H,
Ar-H), 7.15-7.20 (m, 2H, Ar-H); 13C NMR (125 MHz, CDCl3):  −4.8, −4.6, 2.7, 8.4, 18.0, 
25.2, 29.1, 31.9, 47.0, 124.0, 128.1, 128.2, 139.8, 175.9; MS (EI) m/z (%): 273 (M+, 62), 258
(24), 218 (24), 182 (92), 149 (100), 121 (86), 97 (31), 91 (23); HMRS: M+, found 273.15083.
C16H23NOSi requires 273.15488.
trans-2-(2-Oxopyrrolidin-1-yl)cyclopropyl)methylbenzoate 51
Colourless oil; IR(film): max 2924, 1786 (s), 1717 (s), 1682 (s) cm-1; 1H NMR (trans, 300
MHz, CDCl3): 0.94 (m, 1H, CHHCHN), 1.10 (m, 1H, CHHCHN), 1.56 (m, 1H, CHCH2O),
1.97 (m, 2H, CH2CH2N), 2.37, (t, J=8.0, 2H, CH2CON), 2.67 (dt, J=7.6, 3.7, 1H, CHN), 3.31
(t, J=7.0, 2H, CH2N), 4.17 (dd, J=11.6, 7.6, 1H, CHHO2Ph), 4.32 (dd, J=11.6, 6.6, 1H,
CHHO2CPh), 7.44 (dd, J=7.5, 7.9, 2H, meta-Ar), 7.56 (t, J=7.5, 1H, para-Ar), 8.06 (d, J=7.9,
2H, ortho-Ar); 13C(trans, 75 MHz, CDCl3): 10.6, 17.3, 18.0, 30.6, 31.7, 47.5, 66.6, 128.4,
129.6, 130.2, 133.0, 166.6, 176.0; MS (CI+) m/z (%): 260 (M+H, 70), 138 (100); HRMS:
M+H, found: 260.12885. C15H18NO3 requires 260.12866.
endo-1-(1,1a,6,6a-Tetrahydro-cyclopropainden-1-yl)-pyrrolidin-2-one 52
White needles; Mp 53-54 °C (CH2Cl2-Petrol); IR (film): max 3036 (s), 2965 (s), 2912 (s),
2872 (s), 1693 (s) cm-1; 1H NMR (exo, 300 MHz, CDCl3): 1.12-1.26 (m, 1H, CHHCH2N),
1.62 (ddddd, J=11.6, 8.8, 7.9, 4.7, 3.5, 1H, CHHCH2N), 2.05-2.15 (m, 2H, CH2CO), 2.25-
2.33 (m, 1H, CH2CH), 2.45 (ddd, J=9.4, 8.6, 3.5, 1H, CHHN), 2.68 (dd, J 7.1, 6.5, 1H,
ArCH), 2.77 (br t, J=7.1, 1H, CHN), 2.99 (dt, J=9.4, 7.9, 1H, CHHN), 3.05-3.12 (m, 2H,
ArCH2), 7.03-7.10 (m, 3H, Ar-H), 7.29-7.34 (m, 1H, Ar-H); 13C NMR (endo, 125 MHz,
CDCl3): 18.8, 23.2, 28.6, 31.1, 32.2, 34.8, 47.4, 123.7, 124.9, 125.7, 126.2, 139.7, 144.1,
177.5. MS (CI+) m/z (%): 214 (M+H, 100), 129 (60), 98 (42), 86 (40); HRMS: M+H, found:
214.12298. C14H16NO requires 214.12318.
(endo and exo) 1-(1a,2,3,7b-Tetrahydro-1H-cyclopropa[a]naphthalen-1-yl)-pyrrolidin-2-
one 53
Colourless oil; IR (film): max 2926, 2856, 1693 (s) cm-1; 1H NMR (trans, 500 MHz, CDCl3):
(mixture of isomers) 1.40-3.05 (m, 12H, CH2 and CH), 3.25-3.42 (m, 1H), 6.90-7.15 (m, 3H,
Ar-H), 7.20-7.35 (m, 1H, Ar-H); 13C NMR (mixture of isomers, 125 MHz, CDCl3): 17.9,
18.0, 18.1, 18.6, 18.9, 19.5, 21.1, 22.3, 26.0, 27.4, 31.0, 31.7, 34.0, 37.3, 47.3, 47.7, 125.5,
125.8, 125.9, 126.1, 128.5, 128.6, 128.7, 130.3, 133.2, 133.9, 135.4, 135.5, 175.7, 177.7; MS
(EI) m/z (%): 227 (M+, 10), 142 (100), 128 (25), 115 (20), 99 (62), 86 (45); HRMS: M+,
found: 227.13122. C15H17NO requires 227.13101.
Ethyl 2-cis-((2-(2-oxopyrrolidin-1-yl)cyclopropyl)methoxy)acetate 54
Colourless oil; IR (film): max 2980, 1751 (s), 1690 (s) cm-1; 1H NMR (cis, 300 MHz, CDCl3);
0.92 (td, J=6.3, 4.7, 1H, CHHCHN), 1.08 (ddd, J=9.0, 7.7, 6.3, 1H, CHHCHN), 1.27 (t,
J=7.1, 3H, Me), 1.35-1.47 (m, 1H, CHCHN), 1.91-2.03 (m, 2H, CH2CH2N), 2.33-2.41 (m,
2H, CH2CO), 2.54-2.62 (ddd, J=7.7, 6.8, 4.7, 1H, CHN), 3.31 (dt, J=14.7, 7.0, 1H, CHHN),
3.37 (dd, J=10.0, 6.8, 1H, CHHOR), 3.44-3.57 (m, 1H, CHHN), 3.62 (dd, J=10.0, 7.5, 1H,
CHHOR), 4.05-4.25 (m, 4H, CH2Me and CH2CO2Et); 13C NMR (cis, 125 MHz, CDCl3): 8.6,
13.9, 16.6, 18.1, 29.5, 31.4, 48.8, 60.5, 67.6, 70.2, 170.0, 176.9; MS (CI+) m/z (%): 242
(M+H, 71), 214 (39), 195 (31), 138 (100); HRMS: M+H, found: 242.13896. C12H20NO4
requires 242.13923.
1-(2,2,3,3-Tetramethylcyclopropyl)pyrrolidin-2-one 55
Colourless oil; IR (film): max 2924 (s), 2870 (s), 1682 (s) cm-1; 1H NMR (400 MHz, CDCl3):
0.99 (s, 6H, 2 × Me), 1.08 (s, 6H, 2 × Me), 1.72 (s, 1H, CHN), 1.94 (m, 2H, CH2), 2.28 (t,
J=8.0, 2H, CH2CO), 3.29 (t, J 6.9, 2H, CH2N); 13C NMR (100 MHz, CDCl3): 17.6, 18.8, 22.0,
23.2, 31.0, 46.1, 48.6, 177.9; MS (EI) m/z (%): 182 (M+H, 100), 166 (15), 154 (15); HRMS:
M+H, found: 182.15411. C11H21NO requires 182.15448.
3-(2-Benzylcyclopropyl)-2-oxazolidinone 56
Colourless oil; IR (mixture of trans and cis, film): max 3003 (w), 2915 (w), 1742 (s), 1604
(w), 1482 (w), 1419 (w) cm-1; 1H NMR (trans, 500 MHz, CDCl3):  0.82 (dt, J=7.1, 6.1, 1H,
CHHCHN), 1.03 (ddd, J=9.5, 6.1, 3.5, 1H, CHHCHN), 1.36 (dtdd, J=9.5, 6.9, 6.1, 3.5, 1H,
CHCHN), 2.40 (dt, J=7.1, 3.5, 1H, CHN), 2.59 (dd, J=14.5, 6.9, 1H, CHHPh), 2.72
(dd, J=14.5, 6.9, 1H, CHHPh), 3.38-3.42 (m, 2H, CH2N), 4.19-4.25 (m, 2H, CH2O), 7.20-7.32
(m, 5H, Ar-H); 13C NMR (trans, 125 MHz, CDCl3):  13.0, 20.3, 32.1, 37.8, 45.7, 61.8,
126.2, 128.2, 128.3, 140.5, 158.4; 1H NMR (cis, 500 MHz, CDCl3):  0.78 (td, J=6.3, 4.2, 1H,
CHHCHN), 1.05-1.15 (m, 2H, CHHCHN and CHCHN), 2.44 (dd, J=15.4, 9.2, 1H, CHHPh),
2.65 (ddd, J=7.7, 6.9, 4.2, 1H, CHN), 3.11 (dd, J=15.4, 5.1, 1H, CHHPh), 3.51-3.57 (m, 2H,
CH2N), 4.28-4.33 (m, 2H, CH2O), 7.20-7.32 (m, 5H, Ar-H); 13C NMR (cis, 100 MHz,
CDCl3):  11.1, 18.7, 31.0, 33.7, 46.9, 62.0, 126.0, 128.2, 141.0, 159.7; MS (CI+) m/z (%):
218 (M+H, 17), 126 (100), 115 (11), 104 (15), 91 (22), 82 (12), 77 (7), 65 (8), 54 (9) ;
HMRS: M+H, found 218.11777. C13H16NO2 requires 218.11809.
3-(2-tert-Butylcyclopropyl)-2-oxazolidinone 57
Pale yellow oil; IR (film): max 2958, 2869 (s), 1755 (s), 1482 (w), 1423 cm-1; 1H NMR (trans,
500 MHz, CDCl3):  0.75 (td, J=7.3, 5.9, 1H, CHHCHN), 0.80 (ddd, J=9.8, 5.9, 3.7, 1H,
CHHCHN), 0.85 (s, 9H, 3 × Me), 0.95 (ddd, J=9.8, 7.3, 3.7, 1H, CHCHN), 2.35 (dt, J=7.3,
3.7, 1H, CHN), 3.45-3.50 (m, 2H, CH2N), 4.22 (m, 2H, CH2O); 13C NMR (125 MHz, CDCl3):
 9.4, 28.2, 28.7, 29.0, 30.6, 45.8, 61.6, 158.4; MS (EI) m/z (%): 183 (M+, 7), 168 (6), 127
(100), 114 (31), 82 (18), 70 (31), 55 (43), 49 (12), 42 (60); HMRS: M+H, found 184.13305.
C10H18NO2 requires 184.13321.
(±)-Ethyl 2-((1R,2S,5S,6R)-6-(2-oxooxazolidin-3-yl)bicyclo[3.1.0]hexan-2-yl)acetate 58a
and (±)-Ethyl 2-((1R,2R,5S,6R)-6-(2-oxooxazolidin-3-yl)bicyclo[3.1.0]hexan-2-yl)acetate
58b
Pale yellow oil; IR (mixture of 58a and 58b , film): max 2954, 1732 (s), 1417 (s) cm-1; 1H
NMR (major isomer 58a, 500 MHz, CDCl3):  1.20 (t, J=7.2, 3H, CH3), 1.28-1.33 (m, 1H,
CHHCHCH2), 1.35-1.45 (m, 1H, CHHCHCH2), 1.45-1.49 (m, 1H, CHCHN), 1.69-1.72 (m,
1H, CHCHN), 1.78-1.84 (m, 1H, CHHCHCHN), 1.84-1.91 (m, 1H, CHHCHCHN), 2.20 (dd,
J=15.1, 8.2, 1H, CHHCOO), 2.28 (t, J=1.9, 1H, CHN), 2.32 (dd, J=15.1, 7.1, 1H, CHHCOO),
2.62 (br q, J=7.5, 1H, CHCH2CO), 3.47-3.51 (m, 2H, CH2N), 4.14 (q, J=7.2, 2H, CH2CH3),
4.22-4.27 (m, 2H, CH2OCON); 13C NMR (major isomer 58a, 125 MHz, CDCl3):  14.2, 24.7,
24.8, 27.0, 29.7, 33.4, 36.5, 39.8, 45.7, 60.3, 61.8, 158.3, 172.5 ;1H NMR (minor isomer 58b,
500 MHz, CDCl3):  0.68-0.77 (m, 1H, CHHCHCH2), 1.26 (t, J= 7.1, 3H, CH3), 1.60-1.65
(m, 1H, CHCHN), 1.69-1.73 (m, 1H, CHCHN), 1.73-1.79 (m, 1H, CHHCHCH2), 1.79-1.88
(m, 1H, CHHCHCHN), 1.95 (dd, J=12.9, 8.1, 1H, CHHCHCHN), 2.28 (br t, J=1.9, 1H,
CHN), 2.40 (dd, J=15.2, 7.1, 1H, CHHCOO), 2.46 (dd, J=15.2, 7.6, 1H, CHHCOO), 2.56-
2.65 (m, 1H, CHCH2CO), 3.43-3.51 (m, 2H, CH2N), 4.14 (q, J=7.1, 2H, CH2CH3), 4.19-4.28
(m, 2H, CH2OCON); 13C NMR (minor isomer 58b, 125 MHz, CDCl3):  14.3, 25.5, 27.0,
27.6, 28.9, 30.8, 36.6, 37.8, 45.7, 60.3, 61.8, 158.4, 173.0 ; MS (CI+) m/z (%): 254 (M+H,
100), 208 (95), 166 (60), 88 (14); HMRS: M+H, found 254.13872 , C13H20O4N requires
254.13923.
Methyl 3-(1-chloro-2-(2-oxooxazolidin-3-yl)cyclopropyl)-2,2-dimethylpropanoate 5922
White solid; m.p: 46-49 °C (petrol); IR (mixture of trans and cis, film): max 1634 (s), 1427
(w) cm-1; 1H NMR (trans, 500 MHz, CDCl3):  1.28 (s, 3H, CH3CCH3), 1.29 (s, 3H,
CH3CCH3), 1.36 (dd, J=9.0, 7.9, 1H, CHHCHN) 1.59 (ddd, J=7.9, 5.5, 1.0, 1H, CHHCHN),
2.01 (d, J=15.2, 1H, CHHCCHN), 2.11 (dd, J=15.2, 1.0, 1H, CHHCCHN), 2.51 (dd, J=9.0,
5.5, 1H, CHN), 3.56-3.64 (m, 1H, CHHN), 3.68 (s, 3H, CH3O), 3.74-3.80 (m, 1H, CHHN),
4.25-4.37 (m, 2H, CH2OCO); 13C NMR (cis, 125 MHz, CDCl3):  22.0, 25.8, 25.8, 36.7, 42.2,
44.5, 45.6, 48.5, 51.9, 61.9, 158.5, 177.1; MS (CI+) m/z (%): 276 (M+H, 14), 244 (28), 216
(100), 180 (16); HMRS: M+H, found 276.09988, C12H19O4NCl requires 276.10025.
trans-8-endo-(2-Oxooxazolidin-3-yl)-1,4,4-trimethyl-tricyclo[5.1.0.0]octane 60
White solid; m.p: 60-64 °C (petrol); [α]
D
20  = −27.1 (c 1.0, CHCl3); IR (mixture , film): max
2864 (w), 1755, 1634, 1404 cm-1; 1H NMR (endo, 500 MHz, CDCl3):  0.37 (td, J=9.4, 3.2,
1H, CHCMe2), 0.43 (td, J=9.4, 3.2, 1H, CHCMe2), 0.77 (s, 3H, CH3CCHN), 0.82 (m, 1H,
CHCHN), 0.98 (s, 3H, CH3CCH3), 1.02 (s, 3H, CH3CCH3), 1.30 (dd, J=15.7, 3.2, 1H,
CHHCCH3), 1.63 (ddd, J=15.7, 5.8, 3.2, 1H, CHHCHCHN), 2.08 (d, J=7.7, 1H, CHN), 2.27
(dd, J=15.7, 9.4, 1H, CHHCCH3), 2.28 (dd, J=15.7, 9.4, 1H, CHHCHCHN), 3.63 (t, J=7.8,
2H, CH2N), 4.24-4.28 (m, 2H, CH2O); 13C NMR (cis, 125 MHz, CDCl3):  13.9, 15.1, 16.1,
16.9, 17.1, 17.7, 20.3, 21.3, 26.5, 27.8, 38.1, 46.5, 62.4, 159.8 ; MS (CI+) m/z (%): 236
(M+H,43), 149 (100), 100 (22), 88 (48); HMRS: M+H, found 236.16482 , C14H22O2N
requires 236.16505. Anal Calcd for C14H21O2N; C, 71.46; H, 8.99; N, 5.95. Found: C, 71.54;
H, 9.12; N, 5.90.
(E)-Ethyl 5-(2,2-dimethyl-3-(2-oxooxazolidin-3-yl)cyclopropyl)-3-methylpent-2-enoate
61
Pale yellow liquid; IR (mixture of trans and cis, film): max 2955, 1759, 1709, 1643 (s) cm-1;1H NMR (cis, 500 MHz, CDCl3):  0.74 (ddd, J=8.9, 7.6, 5.4, 1H, CHCHN), 1.07 (s, 3H,
CH3CCH3), 1.09 (s, 3H, CH3CCH3) 1.25 (br t, J=7.1, 3H, CH3CH2), 1.34-1.44 (m, 1H,
CHHCH2), 1.76-1.84 (m, 1H, CHHCH2), 2.10 (d, J=7.6, 1H, CHN), 2.14 (s, 3H, CH3C=CH),
2.16-2.22 (m, 1H, CHHC=CH), 2.23-2.31 (m, 1H, CHHC=CH), 3.43-3.56 (m, 2H, CH2N),
4.12 (q, J=7.1, 2H, CH2CH3), 4.22-4.30 (m, 2H, CH2OC=O), 5.64 (br s, 1H, CHCOO); 13C
NMR (cis, 125 MHz, CDCl3):  14.3, 14.9, 18.9, 19.5, 22.8, 22.9, 27.0, 27.8, 40.9, 46.9, 59.5,
62.2, 115.8, 159.5, 160.4, 166.7; MS (FAB) m/z (%): 296 (M+H, 28), 250 (70), 219 (100),
163 (66), 154 (72); HMRS: M+H, found 296.18541, C16H26O4N requires 296.18617.
2-(2-Benzylcyclopropyl)-2,3-dihydro-1-isoindolinone 62
Pale yellow solid; Mp (trans) 62-63°C (i-Pr2O); IR (mixture of trans and cis, film): max 3027
(w), 2914 (w), 1685 (s), 1620 (w), 1496 (w), 1469 (m), 1453 (m), 1408 (m) cm-1; 1H NMR
(trans, 500 MHz, CDCl3):  0.93 (td, J=7.1, 6.0, 1H, CHHCHN), 1.15 (ddd, J=9.6, 6.0, 4.0,
CHHCHN), 1.50 (dtdd, J=9.6, 7.1, 6.4, 3.4, 1H, CHCHN), 2.67 (dd, J=14.7, 7.1, 1H,
CHHPh), 2.80-2.89 (m, 2H, CHN and CHHPh), 4.20 (s, 2H, CH2Ar), 7.20-7.53 (m, 8H, Ar-
H), 7.82 (td, J=7.5, 1.0, 1H, Ar-H); 13C NMR (trans, 125 MHz, CDCl3):  12.8, 20.0, 31.6,
38.2, 50.1, 122.5, 123.4, 126.2, 127.9, 128.4, 128.4, 131.2, 133.2, 140.6, 140.9, 169.3; 1H
NMR (cis, 500 MHz, CDCl3):  0.90-0.97 (m, 1H), 1.11-1.19 (m, 2H), 2.24 (dd, J=15.0, 4.9,
1H, CHHPh), 3.03 (td, J=7.5, 4.5, 1H, CHN), 3.15 (dd, J=15.0, 4.9, 1H, CHHPh), 4.30
(d, J=17.0, 1H, CHHAr), 4.32 (d, J=17.0, 1H, CHHAr), 7.17-7.57 (m, 8H, Ar-H), 7.88 (td,
J=7.4, 1.0, 1H, Ar-H); 13C NMR (cis, 125 MHz, CDCl3):  10.6, 19.2, 30.5, 34.0, 51.8, 122.6,
123.6, 125.9, 128.0, 128.3, 128.4, 131.3, 133.1, 141.1, 141.3, 170.3; MS (EI) m/z (%): 263
(M+, 13), 222 (8), 172 (100), 146 (9), 132 (7), 115 (9), 91 (29), 77 (8), 65 (8), 51 (7); HMRS:
M+, found 263.13096. C18H17NO requires 263.13101.
N-Benzyl-N-(2-benzylcyclopropyl)-acetamide 63
Colourless oil; IR (mixture of trans and cis, film): max 3026 (w), 2924 (w), 1655 (s), 1603
(w), 1495 (w), 1452 (w) cm-1; 1H NMR (trans, 500 MHz, CDCl3):  0.78 (ddd, J=7.1, 6.2,
5.5, 1H, CHHCHN), 0.95 (ddd, J=9.5, 5.5, 4.0, 1H, CHHCHN), 1.37 (ddtd, J=9.5, 7.5, 6.2,
3.5, 1H, CHCHN), 2.16 (s, 3H, Me), 2.33-2.44 (m, 1H, CHN), 2.42 (dd, J=14.5, 7.5, 1H,
CHCHHPh), 2.66 (dd, J=14.5, 6.2, 1H, CHCHHPh), 4.45 (d, J=14.8, 1H, CHHPh), 4.53 (d,
J=14.8, 1H, CHHPh), 7.08-7.12 (m, 4H, Ar-H), 7.19-7.31 (m, 6H, Ar-H); 13C NMR (trans,
125 MHz, CDCl3):  15.9, 22.7, 23.3, 36.8, 37.7, 49.6, 126.3, 126.9, 128.4, 128.5, 138.1,
139.7, 173.3; MS (EI) m/z (%): 279 (M+, 65), 264 (37), 236 (100), 188 (100), 148 (74), 131
(66), 106 (52), 91 (82), 77 (24); HMRS: M+, found 279.16205. C19H21NO requires 279.16231.
trans-3-(2-Benzylcyclopropyl)benzoxazolin-2-one 64
Pale pink solid; Mp 55-57 °C (CH2Cl2-Petrol); IR (film): max 3063, 3026, 2924, 1771 (s),
1612 (w) cm-1; 1H NMR (trans, 400 MHz, CDCl3): 1.08-1.18 (m, 1H, CHHCHN), 1.30-1.42
(m, 1H, CHHCHN), 1.55-1.70 (m, 1H, CHCHN), 2.73 (dt, J=6.7, 3.4, 1H, CHN), 2.76 (dd,
J=14.5, 7.5, 1H, CHHPh), 2.87 (dd, J=14.5, 6.7, 1H, CHHPh), 6.45 (d, J=7.5, 1H, Ar-H),
6.94-7.40 (m, 8H, Ar-H); 13C NMR (trans, 100 MHz, CDCl3): 13.3, 21.0, 28.8, 37.9, 109.0,
109.6, 122.2, 123.5, 126.5, 128.6, 128.7, 131.7, 139.7, 142.1, 154.2; MS (EI) m/z (%): 265
(M+, 65), 224 (25), 175 (55), 130 (100), 115 (50), 103 (90); HRMS :M+H, found: 266.11833.
C16H16NO2 requires 266.11810.
endo-3-(1,1a,6,6a-Tetrahydro-cyclopropainden-1-yl)-3H-benzoxazolin-2-one 65
Pale pink needles; Mp 185-186 °C (CH2Cl2-Petrol); IR (film): max 3042 (w), 3018 (w), 2926
(w), 2853 (w), 1771 (s), 1611 (w) cm-1; 1H NMR (endo, 400 MHz, CDCl3): 2.35-2.42 (m, 1H,
CH2CH), 3.06 (t, J=6.8, 1H, ArCH), 3.12-3.22 (m, 3H, CH2 and CHN), 6.82-6.91 (m, 5H, Ar-
H), 6.94-6.99 (m, 1H, Ar-H), 7.05 (d, J=7.5, 1H, Ar-H), 7.34 (d, J=6.8, 1H, Ar-H); 13C NMR
(endo, 100 MHz, CDCl3): 21.8, 29.5, 32.0, 33.0, 109.6, 109.8, 122.2, 123.1, 123.4, 125.7,
126.1, 126.6, 131.0, 137.7, 142.3, 143.1, 154.5. MS (EI) m/z (%): 263 (M+, 65), 192 (30), 148
(40), 129 (100), 115 (50), 102 (32); HRMS: M+, found: 263.09589. C17H13NO2 requires
263.09462; Anal Calcd for C17H13NO2; C, 77.55; H, 4.98; N, 5.32. Found: C, 77.10; H, 4.89;
N, 5.28.
trans-1-(2-(Hydroxymethyl)cyclopropyl)pyrrolidin-2-one 67
Colourless oil; IR (film): max 3297 (br), 2880, 1674 (s) cm-1; 1H NMR (trans, 300 MHz,
CDCl3): 0.72 (ddd, J=7.5, 6.2, 5.9, 1H, CHHCHN), 0.90 (ddd, J=9.5, 5.9, 4.3, 1H,
CHHCHN), 1.28-1.40 (tddd, J=9.5, 6.2, 5.2, 3.5, 1H, CHCH2OH), 1.90-2.03 (m, 2H,
CH2CH2N), 2.32-2.41 (m, 3H, CHN and CH2CO), 3.15 (dd, J=10.9, 9.5, 1H, CHHOH), 3.26-
3.38 (m, 2H, CH2N), 3.85 (dd, J=10.9, 5.2, 1H, CHHOH); 13C NMR (trans, 75 MHz, CDCl3):
9.3, 17.8, 22.6, 30.2, 31.3, 47.3, 64.5, 177.0; MS (EI) m/z (%): 156 (M+H, 10), 138 (35), 124
(100), 96 (35), 86 (25); HRMS: M+, found: 155.09480. C8H13NO2 requires 155.09462.
(±)-1-((1R,2R,6S,7S)-2-Ethoxybicyclo[4.1.0]heptan-7-yl)pyrrolidin-2-one 69
White solid; Mp 95-97 °C (CH2Cl2-Petrol); IR (film): max 2936 (s), 2864 (s), 1682 (s) cm-1;1H NMR (exo, 500 MHz, CDCl3): 0.97-1.06 (m, 1H, CHHCHOEt), 1.06-1.13 (m, 1H,
CHHCH2CHOEt), 1.17 (t, J=6.9, 3H, Me), 1.30-1.36 (m, 1H, CHHCH2CHOEt), 1.38-1.48
(m, 2H, CHCHN and CHCHOEt), 1.51-1.62 (m, 2H, CHHCHOEt and CHHCHCHN), 1.80-
1.98 (m, 3H, CH2CH2N and CHHCHCHN), 2.29 (t, J=8.2, 2H, CH2CON), 2.51 (br t, J=3.5,
1H, CHN), 3.26 br t, J=6.8, 2H, CH2N), 3.45 (dq, J=15.8, 6.9, 1H, CHHO), 3.73 (m, 2H,
CHHO and CHO); 13C NMR (exo, 125 MHz, CDCl3): 15.5, 17.6, 19.9, 20.5, 21.2, 21.9, 28.0,
31.7, 35.1, 47.5, 63.0, 72.1. 175.7; MS (FAB) m/z (%): 224 (M+, 48), 178 (100) ; HRMS: M+,
found: 224.16480. C13H21NO2 requires 224.16505.
2-Ethoxycyclohex-1-ene 7023
Sodium hydride (60% dispersion in mineral oil, 954 mg, 23.9 mmol) was added portionwise
to a solution of 2-cyclohexen-1-ol (2.21 g, 21.7 mmol) in anhydrous dimethylformamide (15
mL) under nitrogen. After the addition was complete, the reaction was cooled to 0 °C and
iodoethane (5.34 mL, 65.0 mmol) was added dropwise (CAUTION: Exothermic). The
reaction mixture was then allowed to stir at room temperature for 2 hours. Water (50 mL) was
added and the aqueous mixture extracted with ether (2 × 80 mL). The combined organic
layers were washed with brine (50 mL), dried (MgSO4) and concentrated. The residue was
purified by column chromatography (9:1 Petrol:Et2O) to give the ether as a colourless liquid
(620 mg). Elution of the column with 1:1 Et2O:Petrol gave the starting alcohol (660 mg); IR
(film): max 3028, 2922 (s), 2655 (s), 1508, 1456 (s) cm-1; 1H NMR (500 MHz, CDCl3): 1.21
(t, J=6.9, 3H, Me), 1.51-1.58 (m, 1H), 1.67 (dddd, 1H, J=12.0, 9.1, 6.3, 2.5), 1.72-1.86 (m,
2H), 1.91-1.98 (m, 1H), 2.00-2.08 (m, 1H), 3.51 (dq, J=9.1, 6.9, 1H, CHHMe), 3.57 (dq,
J=9.1, 6.9, 1H, CHHMe), 3.81-3.86 (m, 1H, CHO), 5.75-5.79 (m, 1H, HC=CH), 5.81-5.86
(m, 1H, HC=CH); 13C NMR (125 MHz, CDCl3): 15.8, 19.3, 25.2, 28.4, 63.4, 72.6, 128.0,
130.6.
2-(2-tert-Butylcyclopropylamino)ethanol 71
Lithium hydroxide monohydrate (1.24 g, 29.5 mmol, 30 eq) was added in one portion to a
suspension of cyclopropane 57 (0.18 g, 0.98 mmol, 1 eq) in a mixture of absolute ethanol (14
mL) and water (6 mL). The reaction mixture was heated at reflux for 20 h and then allowed to
cool to room temperature. Most of the ethanol was removed in vacuo and saturated aqueous
ammonium chloride (5 mL) was added to the residue. The aqueous layer was extracted with
dichloromethane (2 x 10 mL, then 2 x 5 mL) and the combined organic extracts were dried
(Na2SO4), filtered and concentrated to give the amino alcohol 142 (75 mg, 0.48 mmol, 49%)
as a yellow oil; IR (film): max 3300 (br), 2953 (s), 2866 (m), 1468 (m) cm-1; 1H NMR (500
MHz, CDCl3):  0.34-0.41 (m, 2H, CH2CHN), 0.59 (ddd, J=9.9, 6.2, 3.5, 1H, CHCHN), 0.77
(s, 9H, 3 × Me), 1.95 (dt, J=7.2, 3.5, 1H, CHN), 2.71-2.77 (m, 2H, CH2N), 2.90 (br s, 2H, OH
and NH), 3.57 (t, J=5.5, 2H, CH2OH); 13C NMR (100 MHz, CDCl3):  9.4, 28.5, 28.9, 31.8,
33.3, 51.1, 60.5; MS (CI) m/z (%): 158 (M+H, 100), 100 (86); HMRS: M+H, found
158.154382. C9H20NO requires 158.15448.
tert-Butyl N-[(2-tert-butylcyclopropyl)-(2-hydroxyethyl)]carbamate 72
Di-tert-butyl dicarbonate (106 mg, 0.49 mmol, 1.2 eq) was added portionwise to a solution of
amino alcohol 142 (64 mg, 0.407 mmol, 1 eq) and triethylamine (0.07 mL, 0.51 mmol, 1.25
eq) in dry dichloromethane (2 mL) under nitrogen. After stirring for 24 h, the reaction mixture
was concentrated in vacuo. The crude product was purified by flash column chromatography
(Petrol:EtOAc 4:1 to 3:1) to give the title compound 143 (76 mg, 0.295 mmol, 72%) as a
colourless oil; IR (film): max 3450 (br), 2955 (s), 2870 (m), 1685 (s) cm-1; 1H NMR (500
MHz, CDCl3):  0.65 (ddd, J=9.9, 5.8, 3.9, 1H, CHHCHN), 0.71 (ddd, J=7.5, 6.8, 5.8, 1H,
CHHCHN), 0.82 (s, 9H, 3 × Me), 0.85 (ddd, J=9.9, 6.8, 3.9, 1H, CHCHN), 1.42 (s, 9H,
OC(CH3)3), 2.45 (dt, J=7.5, 3.9, 1H, CHN), 3.29 (ddd, J=14.6, 6.2, 4.6, 1H, CHHN), 3.41
(ddd, J=14.6, 6.5, 4.5, 1H, CHHN), 3.57 (m, 2H, CH2OH); 13C NMR (125 MHz, CDCl3): 
12.2, 28.4, 28.4, 29.1, 32.1, 32.2, 50.7, 62.4, 80.1, 158.2; MS (CI+) m/z (%): 256 (M-H, 100),
200 (30), 182 (32), 156 (45), 147 (65), 138 (29); HMRS: M-H, found 256.191464. C14H26NO4
requires 256.19126.
[tert-Butoxycarbonyl-(2-tert-butylcyclopropyl)-amino]acetic acid 73
An aqueous solution of sodium hydroxide (0.5 M in water, 2.2 mL, 1.1 mmol, 4 eq) and
potassium permanganate (0.65M in water, 1.7 mL, 1.1 mmol, 4 eq) were added successively
to a solution of alcohol 143 (70 mg, 0.27 mmol, 1 eq) in tert-butanol (2.7 mL). The reaction
mixture was stirred for 24 h and then quenched with sodium thiosulfate (5% in water, 7.75
mL). Diethyl ether (10 mL) was added and the mixture was transferred into a separating
funnel. The aqueous layer was separated and then acidified to pH 2 with an aqueous
hydrochloric acid solution (1M) at 4 °C. The mixture was then extracted with EtOAc (3 x 10
mL) and the combined organic extracts were dried (Na2SO4), filtered and concentrated in
vacuo to give the title compound 144 (62 mg, 0.23 mmol, 84%) as a white amorphous solid;
IR (film): max 3450 (br), 2954 (m), 1699 (s) cm-1; 1H NMR (500 MHz, 328K, CDCl3):  0.71
(ddd, J=9.9, 5.7, 3.9, 1H, CHHCHN), 0.75 (ddd, J=7.4, 6.7, 5.7, 1H, CHHCHN), 0.84 (s, 9H,
3 × Me), 0.87 (ddd, J=9.9, 6.7, 3.9, 1H, CHCHN), 1.44 (s, 9H, OC(CH3)3), 2.59 (dt, J=7.4,
3.9, 1H, CHN), 3.83 (d, J=17.7, 1H, CHHN), 4.04 (d, J=17.7, 1H, CHHN), 8.73 (br s, 1H,
OH); 13C NMR (125 MHz, 328 K, CDCl3):  12.2, 28.4, 28.4, 29.0, 32.3, 32.5, 50.0, 80.7,
156.7, 175.3; MS (CI+) m/z (%): 272 (M+H, 33), 216 (92), 172 (52), 154 (100); HMRS:
M+H, found 272.18676. C14H26NO4 requires 272.18617.
2-(1,1a,6,6a-Tetrahydro-cyclopropa[a]inden-1-ylamino)-phenol 74
Lithium triethylborohydride (1.0M in THF, 0.75 mL, 0.75 mmol) was added dropwise to a
solution of cyclopropane 65 (39 mg, 0.15 mmol) in THF (1 mL) under nitrogen. The reaction
mixture was stirred at room temperature overnight and then quenced with saturated
ammonium chloride (4 mL). The aqueous mixture was extracted with ethyl acetate (3 × 10
mL), and the combined organic layers washed with brine (10 mL), dried (MgSO4) and
concentrated. The residue was purified by column chromatography (1:9 EtOAc:Petrol then
3:7 then 1:1) to give the catecolamine 74 as a pale pink solid (12 mg, 34%); IR (film): max
3150-3400 (br), 2924, 1659 (s), 1597 cm-1; 1H NMR (trans, 500 MHz, CDCl3): 2.27 (br q,
J=6.7, 1H, CHCH2Ar), 2.50 (d, J=18.0, 1H, ArCHH), 3.05 (dd, J=8.4, 7.0, 1H, CHAr), 3.12
(dd, J=18.0, 7.0, 1H, ArCHH), 3.73 (t, J=7.0, 1H, CHNH), 6.23 (br s, 1H, NH), 6.76-7.30 (m,
8H, Ar-H), 8.14 (br s, 1H, OH); 13C NMR (trans, 125 MHz, CDCl3): 23.4, 31.3, 31.8, 39.3,
119.6, 120.5, 122.5, 124.5, 124.6, 126.5, 127.0, 127.8, 137.7, 142.7, 150.6, 165.9; MS (CI+)
m/z (%): 266 (100), 238 (23, M+H), 166 (23); HRMS: M+H, found: 238.12343. C16H16NO
requires 238.12318.
4.10.6. 1-[2-(Hydroxycyclopropyl)]-2-pyrrolidinone 75
Tetrabutylammonium fluoride (1 M solution in THF, 1.09 mL, 1.09 mmol) was added to a
solution of cyclopropylsilane 50 (0.54 mmol) in THF (0.3 mL) under nitrogen. After 30 min
of stirring, methanol (1.4 mL), potassium hydrogencarbonate (0.11 g, 1.09 mmol) and
hydrogen peroxide (30% solution in water, 1.12 mL, 10.9 mmol) were added to the solution.
The reaction mixture was stirred for 18 h and then sodium thiosulfate pentahydrate (2.97 g,
11.97 mmol) was added. After stirring for 30 min the mixture was filtered and concentrated in
vacuo. The crude product was then purified by flash column chromatography to give the
desired amino cyclopropanol as a colourless oil (35%); IR (film): max 3369 (br), 2989 (w),
2957 (w), 2859 (w), 1662 (s), 1463, 1425 cm-1; 1H NMR (500 MHz, CDCl3):  0.83 (ddd,
J=7.5, 7.1, 5.0, 1H, CHHCHN), 1.02 (ddd, J=8.7, 7.1, 4.1, 1H, CHHCHN), 1.85-1.99 (m, 2H,
CH2CH2N), 2.33 (t, J=8.1, 2H, CH2CO), 2.53 (ddd, J=8.7, 5.0, 1.6, 1H, CHN), 3.20-3.30 (m,
2H, CH2N), 3.50 (ddd, J=7.5, 4.1, 1.6, 1H, CHOH), 4.31 (br s, 1H, OH); 13C NMR (125
MHz, CDCl3):  14.6, 17.9, 31.6, 32.4, 47.4, 51.1, 176.6; MS (EI) m/z (%): 141 (M+, 7), 112
(100), 98 (24), 84 (23), 69 (47); HMRS: M+, found 141.07832. C7H11NO2 requires 141.07843.
References
1. Salaün, J. Top. Curr. Chem. 2000, 207, 1-67; Salaün, J.; Baird, M. S. Curr. Med. Chem.
1995, 2, 511-542; Gnad, F.; Reiser, O. Chem. Rev. 2003, 103, 1603-1623; Stammer, C. H.
Tetrahedron, 1990, 46, 2231-2254; Burgess, K.; Ho, K. –K.; Moye-Sherman, D. Synlett,
1994, 575-583.
2. Vilsmaier, E. The Chemistry of the Cyclopropyl Group; Rappoport Z., Ed, John Wiley &
Sons: Chichester, 1987, p 1341.
3. Asunskis, J.; Shechter, H. J. Org. Chem. 1968, 33, 1164-1168; Wurz, R. P.; Charette, A. B.
J. Org. Chem. 2004, 69, 1262-1269.
4. Kang, J.; Kim, K. S. J. Chem. Soc. Commun. 1987, 897-898.
5. Aggarwal, V. K.; de Vicente, J.; Bonnert, R. V. Org. Let. 2001, 3, 2785-2788; Tsai, C. –C.;
Hsieh, I. –L.; Cheng, T. –T.; Tsai, P. –K.; Lin, K –W.; Yan, T. –H. Org. Let. 2006, 8,
2261-2263.
6. de Meijere, A.; Kozhushkov, S. I.; Savchenko, A. I. J. Organomet. Chem. 2004, 689, 2033-
2055.
7. Brookhart, M.; Studabaker, W. B. Chem. Rev. 1987, 87, 411-432; Merino, I.; Hegedus, L.
S. Organometallics 1995, 14, 2522-2531; Barluenga, J.; López, S.; Trabanco, A. A. ;
Flórez, J. Chem. Eur. J. 2001, 7, 4723-4729; Barluenga, J.; Aznar, F.; Gutiérrez, I.;
García-Granda, S.; Llorca-Baragaño, M. A. Org. Let. 2002, 4, 4273-4276.
8. Motherwell, W. B.; Roberts, L. R. J. Chem. Soc. Commun. 1992, 1582-1583; Motherwell,
W. B.; Roberts, L. R. Tet. Let. 1995, 36, 1121-1124; Motherwell, W. B. J. Organomet.
Chem. 2001, 624, 41-46; Motherwell, W. B. Pur. Appl. Chem. 2002, 74, 135-142.
9. Motherwell, W. B.; O’ Mahony, D. J. R.; Popkin, M. E. Tet. Let. 1998, 39, 5285-5288.
10. Fletcher, R. J.; Motherwell, W. B.; Popkin, M. E. Chem. Comm. 1998, 2191-2192.
11. Bégis, G.; Cladingboel, D. E.; Motherwell, W. B. Chem. Comm. 2003, 2656-2657.
12. Bégis, G.; Cladingboel, D. E.; Motherwell, W. B.; Sheppard, T. D.; Tocher, D. A.
Synthesis 2005, 3186-3188.
13. Gmeimer, P.; Bollinger, B. Synthesis 1995, 168-170
14. Norman, M. H.; Minick, D. J.; Rigdon, G. C. J. Med. Chem. 1996, 39, 149-157.
15. Chan, J. H. –H.; Rickborn, B. J. Am. Chem. Soc. 1968, 90, 6406-6411; Denmark, S. E.;
Edwards, J. P. J. Org. Chem. 1991, 56, 6974-6981.
16. Tanaka, H.; Ogasawara, K. Tet. Let. 2002, 43, 4417-4420.
17. Koldobskii, A. B.; Vakhmistrov, V. E.; Solodova, E. V.; Shilova, O. S.; Kalinin, V. N.
Dokl. Chem. Eng. Trans. 2002, 387, 289-292.
18. Treppendahl, S.; Jakobsen, P. Acta. Chem. Scand. Ser. B. 1982, 36, 275-276.
19. Molander, G. A.; Harris, C. R. J. Org. Chem. 1997, 62, 2944-2956.
20. Troxler, T.; Scheffold, R. Helv. Chim. Act. 1994, 77, 1193-1202.
21. Inoue, S. –I.; Takaya, H.; Tani, K.; Otsuka, S.; Sato, T.; Noyori, R. J. Am. Chem. Soc.
1990, 112, 4897-4905.
22. The alkene 36 was purchased from the Aldrich chemical company (cat number 35,773-1)
but is no longer commercially available.
23. Baguley, P. A.; Walton, J. C. J. Chem. Soc. Perkin Trans. I 1998, 2073-2082.
